TIGIT is an inhibitory receptor containing T cell immunoglobulin and immune receptor protein tyrosine inhibitory motif domain. It shows high expression level on the surface of immune cells in tumor patients and plays an inhibitory role by binding to corresponding ligands, CD155 and CD112. Studying the mechanism of inhibitory effect of TIGIT and the way to block it shows a great significance in the immunotherapy of tumor. In this review, the structure of TIGIT molecule and its inhibitory effect on immune cells(including NK cells and T cells) were introduced, the expression level and the newest research advance of TIGIT molecule in lymphoma,multiple myeloma,leukemia and myelodysplastic syndrome were reviewed and summarized briefly, so as to provide reference for the further study of TIGIT and the application of TIGIT inhibitors in hematological malignancies.
题目: 免疫检查点分子TIGIT在血液恶性肿瘤中的研究进展.
摘要: TIGIT是一种含有Ｔ细胞免疫球蛋白和免疫受体蛋白酪氨酸抑制模体结构域的抑制性受体，高表达于肿瘤患者的免疫细胞表面，通过与相应配体CD155和CD112结合发挥抑制作用。研究TIGIT分子发挥抑制作用的机制并阻断该分子，在肿瘤的免疫治疗中具有重大意义。本文介绍了TIGIT分子的结构及其对免疫细胞（包括NK细胞和T细胞）的抑制作用，并对TIGIT分子在淋巴瘤、多发性骨髓瘤、白血病以及骨髓增生异常综合征中的表达水平及最新研究进展进行综述，旨在为TIGIT在血液恶性肿瘤中作用的进一步研究及其抑制剂的临床应用提供参考.